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EXTENDED ABSTRACT 
The  past  twenty  years  have  witnessed  the 
high-speed  growth  of  China’s  biotechnology 
industry, and this presents an excellent opportunity 
to  examine  the  changes  that  have  taken  place, 
especially,  to  carry  out  overall  evaluation  and 
governance  analysis  from  the  perspective  of 
technology  policies.  Although  China’s 
biotechnology  industry  has  achieved  tremendous 
extension both in scale and structure, the strengths 
it  gained  from  basic  research  have  been 
significantly weakened by commercialization. This 
has resulted in the comparatively limited scale of 
the  whole  industry,  innovation-lacking  products, 
poor  output  from  research  and  development  and 
scarcity of industrial resources. A large range of 
literature  regarding  China’s  biotechnology 
industry  attributes  these  outcomes  to  vague  and 
even inappropriate governance, findings supported 
mainly by analyses based on the linear model of 
impact  of  government  policies  on  industrial 
development.  In  these  analyses,  government, 
enterprises  and  companies  as  well  as  R&D 
organizations are either put on the opposite poles 
or in a straight line.   
After  examining  the  nature  of  China’s 
biotechnology  industry,  and  in  particular  the 
dynamic procedures in research and development, 
the  authors  of  this  paper  argue  that  besides 
government, enterprises and R&D organizations, a 
diverse  array  of  factors  should  be  taken  into 
account  as  we  tackle  issues  emerging  in 
understanding  the  development  of  China’s 
biotechnology industry. Furthermore, these factors, 
human  or  nonhuman,  should  not  be  arranged  as 
opposing poles or linearly connected points on a 
straight  line.  They  are  in  fact  all  knitted  in 
networks  and  act  as  both  knitters  and  knots. 
China’s biotechnology industry gains its strength 
to develop and evolve from these networks, thus 
its governance must be aimed at improving their 
stability and quality.   
Although the main disciplinary perspectives of this 
research are historical and sociological (including 
identification of the  three development stages of 
biotechnology  in  China  since  1978  to  present 
days), a large number of concepts and ideas from 
management studies as well as an interdisciplinary 
approach are also incorporated into the analysis.   
The  main  model  used  in  this  research  is  Actor 
Network  Theory,  which  is  employed  as  a  basic 
theoretical  frame.  From  this  starting  point  the 
authors attempt to make a closer examination of 
China’s biotechnology industry both at the level of 
technology research  and development  and  at  the 
level of commercialization. The modeling process 
in this research can be regarded as an attempt to 
explore  the  social  construction  of  China’s 
biotechnology  industry.  The  paper  reveals  how 
China’s  biotechnology  industry  develops  in  the 
form  of  networks  within  the  country’s  social 
context  and  what  kinds  of  relationships  exist 
among  the  relevant  factors;  therefore,  providing 
guiding insights for improving the governance of 
China’s biotechnology industry both in policy and 
management. 
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1.  INTRODUCTION 
The  last  few  decades  witnessed  the  high-speed 
growth of China’s biotechnology industry, which 
has currently become a focus of academic research 
not only in economics but also in a large array of 
other fields such as management and policy studies. 
Because  of  the  strong  relationships  between 
biotechnology as  an industry and as science and 
technology  (S&T)  development,  China’s 
biotechnology industry can also serve as a study 
objective  in  S&T  Studies  (STS).  Therefore,  a 
useful approach to examining its evolution can rise 
out of the sociology of S&T (Biagioli, 1999).   
As  the  main  outlet  of  biomedical  and 
biotechnological research, bio-pharmacy plays the 
role of a knot between basic biologic research and 
biotechnology  industry.  The  picture  of  China’s 
biotechnology industry will be incomplete without 
a  systematic  analysis  of  the  country’s 
bio-pharmaceutical  industry,  which  share  in 
China’s  biotechnology  industry  has  increased 
steadily  in  the  past  twenty  years.  Although 
bio-pharmacy is a subset of the total biotechnology 
sector,  it  is  the  main  focus  of  the  analysis  here 
because  of  the  growth  potential  it  holds  (other 
biotechnology subsets such as genetic testing, gene 
therapy  or  environmental  biotechnology  are  less 
likely to become large industrial applications). 
In  this  paper,  the  bio-pharmaceutical  industry  is 
taken as the key point for systematically analyzing 
the  evolution  of  the  biotechnology  industry  of 
China.  By  employing  Actor  Network  Theory  as 
the main theoretical frame, we attempt to explore 
China’s biotechnology industry both at the level of 
technology research and development (R&D) and 
at the level of commercialization, in order to reveal 
how this industry develops in the form of networks 
within  a  social  context  and  what  kinds  of 
relationships  exist  among  any  relevant  factors 
thereby  unknotting  the  problems  that  have 
emerged.  The  last  section  considers  the  policy 
implications from our findings.   
2.  EVOLUTION OF CHINA’S 
BIOTECHNOLOGY INDUSTRY     
China has a long history of biomedicine, and from 
the  age  of  legend,  traditional  forms  of 
biotechnology have existed. It is widely believed 
that Shen Nong who was generally regarded as the 
god of agriculture, invented a transparent stomach 
covering in order to observe the effects of herbal 
medicines  on  the  digestive  tract.  In  the  Sui 
Dynasty  (581-618),  a  vaccine  against  smallpox 
was  developed,  and  during  the  Ming  Dynasty 
(1368-1644),  it  became  widely  available  to  the 
masses.  Despite  this  early  inventiveness,  China's 
biotechnology failed  to go through the  explosive 
changes as western science did in the 17
th to 19
th 
centuries.  As  noted  by  Needham  (1954),  China 
never  underwent  a  scientific  revolution  until  the 
foundation of  the People’s Republic of China in 
1949.  Soon  after  that,  with  the  “Great  Leap 
Forward” policy (which was initially launched in 
1958  in  an  effort  to  catch  up  with,  and  try  to 
surpass,  the  technological  development  of  the 
industrially advanced countries) Chinese scientists 
succeeded  first  in  the  world  in  synthesizing  the 
crystalline bovine insulin on 17 September 1965, 
signifying a crucial step in understanding life and 
exploring its secrets. This discovery however did 
not  bring  the  first  light  of  morning  to  the 
development  of  China’s  modern  biotechnology 
industry. 
In the 1970s, recombinant DNA was developed to 
isolate  and  characterize  deoxyribonucleic  acid 
(DNA),  which  allowed  scientists  to  work  with 
living  systems  (Hara,  2003).  The  transfer  of 
genetic information into living organisms provides 
the  means  to  produce  valuable  pharmaceuticals 
and cure human genetic diseases. The development 
of biotechnology in the West was thus accelerated, 
however,  China  was  still  in  the  throes  of  the 
Cultural  Revolution,  and  Chinese  scientists  had 
little chance to participate in the development of 
modern biotechnology. It was not until 1978 that 
China’s biotechnology as well as a large array of 
scientific research programs were initiated in the 
“Spring  of  Sciences”.  The  three  stages  in  the 
development  of  China’s  biotechnology  industry 
that followed are described below. 
2.1 First stage: initial starting   
In 1978, biotechnology was first  mentioned as a 
focal point of China’s S&T development program. 
Following  that,  it became  the top priority  in  the 
high technology field (Hamer and Kung, 1989). 
During the Sixth 5-Year Plan (1981-1985), funds 
were allocated to support biotechnology research 
in  the  fields  of  agriculture,  food  processing  and 
pharmaceutical  production.  From  1981  to  1985, 
the funding for biological research increased more 
than  25-fold,  and  new  mechanisms  were 
introduced to allocate these monies by competitive, 
peer-reviewed grants. In 1983, the China National 
Center for Biotechnology Development (CNCBD) 
was  established  to  coordinate  the  country’s 
biotechnological research activities.   
During the Seventh 5-Year Plan (1986-1990), the 
level  and  scope  of  biotechnology  funding  also 
increased  greatly,  and  around  1989,  China's 
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investment in biotechnology, as a percentage of its 
gross national product, was comparable to that in 
many western countries. In March 1986, the State 
Council  Leading  Group  on  S&T  of  China 
published a pivotal document and launched “The 
National  High  Technology  Research  and 
Development  Program  of  China”,  regularly 
referred  to  as  the  "863  Plan",  which  confirmed 
biotechnology as the top priority in China's high 
technology development program. That same year, 
the National Natural Science Foundation of China 
(NSFC) came into being to support biotechnology 
as well as other basic research. In 1988, the State 
Science  and  Technology  Commission  (SSTC) 
published  the  white  paper  on  S&T,  which 
reinforced  biotechnology  as  China's  number  one 
priority  for  high  technology  development.  These 
events  in  effect  set  the  stage  for  the  current 
mechanisms  for  determining  biotechnology 
research priorities, administration and funding. In 
this  period,  the  total  investment  in  China’s 
biotechnology  and  closely  related  fields  was 
approximately  100  million  yuan,  or  20  million 
yuan  per  year.  These  monies  were  provided 
through the  Chinese Academy of Science (CAS) 
and the  Ministries of Agriculture, Public Health, 
Medicine and Light Industry. In 1987 for instance, 
108 projects out of a pool of 150 applications were 
approved  and  supported;  the  average  grant  was 
200,000  yuan,  and  certain  key  projects  were 
funded  up  to  2  million  yuan  (Hamer  and  Kung, 
1989). The areas of research solicited and funded 
by  the  Seventh  5-Year  Plan  mainly  focused  on 
basic  genetic  engineering,  plant  genetic 
engineering,  chromosome  engineering,  cell 
engineering,  enzyme  engineering,  downstream 
processing and bioengineering products.   
China started to show  interest for  a presence on 
international markets but the numbers of registered 
foreign  patents  were  quite  small.  During 
1978-1995, there were only 150 US patents (105 in 
pharmaceuticals  and  92  for  other  biotechnology 
products)  by  Chinese  nationals
1.  By  the  end  of 
1996,  two  new  types  of  research  centers  were 
inaugurated in China to promote the development 
and  commercialization  of  this  field.  Firstly,  two 
Biotechnology  Bases  located  respectively  at 
Jiangmen and Shanghai, designed to bring research 
results  to  the  production  stage  were  established. 
Secondly, ten State Key Laboratories (summarized 
in Table 1) carried out most of the basic research 
and provided research training for scientists from 
throughout China. 
                                                        
1
Data  retrieved  from  the  US  Patent  and  Trademark 
Office. 
2.2 Second stage: steady growth 
During  the  Ninth  5-Year  Plan  (1996-2000), 
China’s biotechnology industry embraced the stage 
of steady growth in scale. There were 39 publicly 
trading biopharmaceutical firms in China by 2000, 
and China has co-operated with 152 countries in 
science and technologies and signed bilateral S&T 
co-operation  agreements  with  99  governments 
(Ding,  2007).  During  this  period,  the 
biotechnology sector enjoyed substantial scientific 
success and grew steadily to a considerable size. 
China’s  ambition  for  a  presence  in  the  global 
market was demonstrated with a total of 217 (156 
pharmaceutical  and  177  for  other  biotechnology 
products) patents registered in USA
1. 
Table 1 China’s State Key Laboratories in 
biotechnology 
Year of   
Establishment 
Location  Name 
1984  FuDan University, 
Shanghai 
State Key Lab of 
Genetic Engineering 
1985  Beijing University, 
Beijing 
State Key Lab of 
Natural and 
Biomimetic Drugs 
1985 
Shanghai Cancer 
Institute & Jiaotong 
University, 
Shanghai 
State Key 
Laboratory of 
Carcinogenesis 
1989    Zhong’nan 
University, Hu’nan 
National Lab of 
Medical Genetics of 
China 
1991    Nanjing University, 
Jiangsu 
State Key Lab of 
Pharmaceutical 
Biotechnology 
1991    Academy of 
Science, Beijing 
State Key Lab of 
Medical molecular 
biology 
1991   
Shanghai Institute 
of Material 
Medica, Academy 
of Science, 
shanghai 
State Key Lab of 
New Drug Research 
1991   
East China 
University of Sci & 
Tech, shanghai 
State Key 
Laboratory of 
Bioreactor 
Engineering 
1992    FuDan University, 
Shanghai 
State Key Lab of 
Medical 
Neurobiology 
1996    Qinghua 
University, Beijing 
Lab of Structural 
Biology 
 
Figure 1. Value added of pharmaceutical industry in China 
(100 million yuan) 
Source:  National  Bureau  of  Statistics  et  al,  China  Statistics 
Yearbook on High Technology Industry (2005). 
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For  example,  recombinant  human  interferon 
Europium  αlb,  the  first  Chinese  production  of 
genetically  engineered  drugs,  which  is  also  the 
world's  first  genetic  engineering  drugs  using 
Chinese  gene  cloning  and  expression,  was 
developed  in 1989, and it  is so far  the only one 
with  self-owned  intellectual  property  developed 
independently  by  Chinese  scientists.  Following 
this, the bio-pharmaceuticals grew at a high speed:   
12 genetic engineering pharmaceuticals came into 
the market of China in 1996, the proceeds of sale 
were  0.22  billion  yuan  which  increased  to  0.72 
billion yuan in 1998 and 2.28 billion yuan in 2000 
with  an  average  annual  growth  rate  of  79% 
(DHTID,  2003).  In  1996,  the  output  value  of 
biotechnology pharmaceuticals was approximately 
1.8 billion yuan with profits of 0.5 billion yuan, 
while a year later, their output value increased to 3 
billion yuan, and at the end of 2000, this number 
doubled to 6.9 billion yuan. The added value of 
pharmaceutical  industry  also  increased 
significantly (see Figure 1), and there were more 
than  300  enterprises  producing  more  than  20 
bio-technological pharmaceuticals in China. 
Despite the progress made during the period of the 
Ninth 5-year Plan, China’s biotechnology industry 
confronted  a  series  of  problems  which  would 
impede its further development. As during the first 
period,  in  the  Ninth  5-year  Plan  biotechnology 
research  remained  funded  almost  entirely  by  the 
Chinese  government  (Wang,  2002).  Although 
there were hundreds science-based companies and 
research  institutes,  the  biotechnology  sector 
remained largely an academic affair because of the 
little  discovery  ability  and  capacity  in  China’s 
bio-pharmaceutical field. Few patented drugs were 
developed with commercial purpose. Even worse, 
the  missed  opportunities  in  small  molecule  and 
antibody  therapy  restricted  the  market  expansion 
of China’s bio-pharmaceutical industry in its most 
recent stage. 
2.3 Third stage: accelerated extension 
In 2001 the Chinese government started the Tenth 
5-year Plan (2001-2005). Under it the development 
of the biotechnology industry was characterized by 
accelerated  extension:  the  annual  output  of  the 
Chinese  fermentation  industry  stood  at  US$  20 
billion;  nearly  400  thousand  tons  of  industrial 
enzymes  are  produced  every  year;  the  bio-diesel 
production  capacity  is  about  100,000  tons  and 
China has the world-leading enzymatic technology 
for  bio-diesel  production.  The  annual  production 
of  methane  is  approximately  5.6  billion  m
3,  and 
China  has  become  the  largest  producer  of 
antibiotics, glutamic acid, citric acid and vitamin C. 
The number of US patents with Chinese inventors 
almost doubled to 414 (238 for pharmaceutical and 
270 for other biotechnology products)
1. By the end 
of  this  period,  each  indicator  of  the  whole 
pharmaceutical industry greatly exceeded the plan: 
industrial output value, industrial added value and 
total profits more than doubled those of the Ninth 
5-year Plan (Fang, 2006-7).   
Apart from the expansion in  industrial scale,  the 
economic structure of China’s bio-pharmaceutical 
industry  further  improved.  By  accelerating  the 
organizational structure adjustment and enlarging 
their  sizes  via  recombination  and  shareholding 
reforms,  a  number  of  large-scale  enterprises 
became listed in the Shanghai and Shenzhen stock 
exchanges.  On  the  other  hand,  many  small  and 
medium-sized  enterprises  (SMEs)  were  still 
confronted  with  shortage  of  intellectual  property 
rights,  low  R&D  expenditure  and  technological 
inferiority, which was determined by the industry’s 
inborn  high  demands  in  technology,  capital  and 
R&D. Nevertheless, during the Tenth 5-year Plan 
period,  especially  after  China  joining  the  World 
Trade  Organization  (WTO),  more  and  more 
foreign-funded  enterprises  surged  in  China’s 
high-end  bio-pharmaceutical  market.  While 
forcing  the  domestic  bio-pharmaceutical 
enterprises to constantly reform and integrate so as 
to  improve  their  degree  of  concentration  and 
competitive  ability,  they  would  also  wash  out 
completely  most  SMEs.  Together  with  the 
inner-industry  or  cross-industry  merger  and 
reorganization  in  bio-pharmaceuticals,  the 
structure  of  China’s  biotechnology  industry 
became much better balanced. 
In this stage, biotechnology research and industry 
development in China entered a new era with the 
creation  of  a  national  biotechnology  leadership 
group.  Funding  for  biotechnology  research  came 
from  two  sources:  government  and  enterprises. 
From 2000 to 2005, the Chinese government has in 
total spent about 10 billion yuan on biotechnology 
research mainly  through the  Ministry of Science 
and  Technology  (MOST),  NSFC,  CAS  and 
relevant  local  government;  among  these,  MOST 
administrated  more  than  half  of  the  government 
funding. Besides government funding, companies 
were estimated to invest roughly 500 million yuan. 
As a result from the strong emphasis on research 
and development, 30 types of new biotech-drugs 
were commercialized in this period, and over 150 
biotechnology products were in clinical trials, the 
annual  growth  rate  of  the  bio-pharmaceutical 
industry was more over 20%.   
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3.  CHINA’S BIOTECHNOLOGY IN 
ACTOR NETWORKS 
From  1996  onwards,  the  industrial  scale  and 
structure of  China’s biotechnology  industry have 
improved tremendously, however, the past twenty 
years  also  saw  the  strength  this  industry  gained 
from basic research significantly weaken, namely 
in  the  progression  to  commercialization,  the 
comparatively limited scale of the whole industry, 
innovation-lacking products and poor output from 
R&D.  It  is  commonly  assumed  that  these  issues 
were caused by somewhat vague and inappropriate 
governance.  However  after  examining  closer 
China’s biotechnology  industry within  the model 
of Actor  Network  Theory  (ANT),  we  argue  that 
besides  government,  enterprises  and  R&D 
organizations,  a  diverse  array  of  factors  should 
also  be  taken  into  account;  furthermore,  the 
relationships  among  them  determine  the  stability 
of  the  whole  networks,  therefore  driving  the 
development of China’s biotechnology industry.   
3.1 Actor Network Theory 
Initially  created  in  an  attempt  to  examine  the 
processes of innovation and knowledge-creation in 
S&T, ANT was first put forward by Michel Callon 
and  Bruno  Latour  in  the  early  1980s  (Yearley, 
2005).  By  analyzing  large  scale  technological 
developments  in  an  even-handed  manner  to 
include  political,  organizational,  legal,  technical 
and scientific factors and insisting on the agency 
of  nonhumans,  ANT  maps  the  simultaneously 
material  and  semiotic  relations  in  heterogeneous 
associations of humans and nonhumans, so as to 
explain  how  material-semiotic  networks  come 
together to act as an apparently coherent whole and 
explore  how  actor  networks  are  formed,  hold 
themselves together or fall apart. Since 1990, ANT 
is widely adopted as an approach for analysis of 
heterogeneous relations in organizational analysis, 
health  studies,  sociology,  anthropology,  feminist 
studies,    economics and so forth.   
As one of the core concepts in ANT, translation 
serves  as  the  basic  tool  for  understanding  the 
development  of  technology.  In  the  course  of 
translation, innovators attempt to create a forum, a 
central network in which all the actors agree that 
the network is worth building and defending. Four 
moments  of  translation  are  defined  by  Michel 
Callon (1998; en.wikipedia.org): Problematisation, 
Interessement,  Enrolment  and  Mobilization.  The 
first moment allows to get delegates representing 
various groups of actors  identified,  including the 
primary  actor  who  tries  to  establish  itself  as  an 
Obligatory Passage Point (OPP) between the other 
actors  and  the  network,  therefore  making  itself 
indispensable.  Interessement  makes  the  actors 
interested  and  negotiate  the  terms  of  their 
involvement.  The  primary  actor  now  works  to 
convince  the  other  actors  that  the  roles  it  has 
defined for them are acceptable. During Enrolment 
the actors accept the roles that have been identified 
for  them,  which  results  in  the  enrolment  of  all 
relevant human and nonhuman factors as Actants. 
The  last  moment,  Mobilization,  ensures  the 
enrolment is actively supported, and the delegate 
actors adequately represent the masses.   
Holding  the  rationale  that  differences  between 
human and nonhuman actors are generated in the 
network of relations, it should not be presupposed, 
ANT  argues  that  all  the  elements  in  a  network, 
human  and  nonhuman,  can  and  should  be 
described  in  the  same  terms.  This  is  called  the 
principle of generalized symmetry. Furthermore, it 
talks of Actants to denote human and nonhuman 
actors,  and assumes  that the  actors  in a network 
take  the  shape  that  they  do  by  virtue  of  their 
relations with one another. It assumes that nothing 
lies outside the network, and suggests that there is 
no difference in the ability of technology, humans, 
animals  or  other  nonhumans  to  act.  The  ANT 
model notes that as soon as an actor engages with 
an actor network it too is caught up in the web of 
relations and becomes part of the entelechy. 
3.2  Actor  Networks  of  China’s  biotechnology 
industry 
The set of reforms have set China’s biotechnology 
industry on a solid footing as an innovation system, 
through the reorganization of R&D organizations 
and the promotion of heterogeneous relationships 
among  various  actors  embedded  in  the  social 
context. Nevertheless, the networks of the Chinese 
biotechnology  industry  are  still  confronted  with 
instability,  which  in  the  large  extent  causes 
biotechnological products to be hard to move from 
the  laboratory  to  the  market.  The  excellence  in 
science  as  well  as  the  expertise  available  in 
universities and public research institutions are far 
from being exploited to their full potential. 
From the initial stage of development, the Chinese 
government  has  retained  the  position  of  OPP 
between actors and networks in the biotechnology 
industry.  Evidence  of  this  is  the  mainly 
government funded biology research and industrial 
development (see Table 2). Through the national 
system of administration, the Chinese government 
strengthens the linkage between the enrolled actors 
after getting delegates representing the groups of 
actors  identified,  so  as  to  enable  the  actors  to 
negotiate  the  terms  of  their  involvement  while 
holding  that  their  roles  assigned  by  government 
2697 
were acceptable. By mobilization, the networks of 
China’s  biotechnology  industry  became  widely 
supported,  and  the  delegate  actors  adequately 
represented the masses. Therefore, the interests of 
different  human  and  nonhuman  actors  were 
translated into the interests of the whole networks.   
In  the  R&D  section  of  biotechnology,  networks 
made by human actors, mainly scientists, funding 
bodies  and  administrative  staff,  and  nonhuman 
actors (facilities, research money, plants, animals 
and  so  forth)  were  linked  by  programs.  These 
programs  were  initiated  by  the  Chinese 
government to launch the translation of interests. 
During the moments of translation, the formation 
and stability of networks were ensured by funding 
and  administration  mainly  from  MOST  (which 
conducted 973, 863, Torch, and Special Programs), 
NSFC (which focused on basic research), National 
Development  and  Reform  Commission  (NDRC) 
responsible  for  industry  development  and 
industrial  policy,  the  State  Food  and  Drug 
Administration  (SFDA),  CAS  supporting  related 
institutes,  and  Ministry  of  Education  (MOE) 
supporting related universities. Among  them,  the 
Bureau  of  Life  Science  and  Biotechnology 
affiliated  with  the  Chinese  Academy  of  Science 
demonstrated well the OPP  position  the  Chinese 
government has set for itself in the networks. With 
21  research  institutes,  3  biotech  research  bases 
(Shanghai, Beijing, West-South China), over 6000 
R&D personnel, 7 focused research area, 2 Priority 
development areas (Biotechnology and Pharmacy), 
the  Bureau  created  a  token  of  China’s 
biotechnology R&D in the form of network. 
Table 2 R&D by source of funds and sector of 
performance, 2004 (billion yuan) 
Source: Annual S&T report, MOST 2005 
The  successful  formation  and  consolidation  of 
networks guaranteed the accelerated development 
of  China’s  biotechnology  industry.  China’s 
participation as the only developing country in the 
Human  Genome  Project  (HGP)  and  Chinese 
researchers  successfully  sequencing  1%  of  the 
human  genome  with  an  accuracy  rate  of  99%, 
showcased  the  country’s  capability  in 
biotechnological  research  (Breithaupt,  2003). 
Nevertheless,  both  the  quality  and  stability  of 
China’s biotechnology industry networks need to 
be  improved.  There  are  currently  approximately 
500 bio-pharmaceutical companies in China with 
annual  sale  proceeds  of  about  34  billion  yuan, 
however,  the  share  it  occupies  in  the  whole 
pharmaceutical market is less than 10%. The lack 
of group-scale enterprises, poor competitive power, 
innovation-lacking  products,  pressure  from 
foreign-owned  enterprises’  entering  and  further 
limitations are weakening the strength of China’s 
biotechnology industry networks.   
4.  CONCLUSION: POLICY IMPLICATIONS 
Biotechnology continues to be the top priority for 
China’s 2006-2020 S&T Development Plan (Ding, 
2007).  Despite  the  rapid  growth  achieved  in  the 
past twenty years, China’s biotechnology industry 
still has a large range of restricting actors which 
severely  threaten  the  whole  networks.  Among 
these  actors,  limited  funding,  low  investment, 
insufficient  research  personnel  and  domestic 
collaboration are ranked at the top of the list.   
The shortage of financing options creates the first 
major  bottleneck  for  the  Chinese  biotechnology 
industry. The government remains the main source 
of  funding  for  R&D  and  commercialization. 
Besides,  China’s  biotechnology  enterprises  also 
find  it  particularly  difficult  to  attract  investment 
because  of  the  short-term  expectations  of  the 
Chinese  investor  community.  Investors  in  China 
are focused on returns on investment that can be 
received  more  rapidly  than  what  is  typical  for 
health biotechnology ventures, renowned for their 
risky nature and protracted development times. As 
a  result,  Chinese  companies  have  steered  away 
from high-risk, capital-intensive R&D activity and 
toward commercialization of more mature and less 
risky technologies such as in generic manufacture 
(see Figure 2).   
Insufficient  research  personnel  and  domestic 
collaboration resulting from the scattered industrial 
structure  are  also  challenging  the  stability  of 
China’s  biotechnology  industry  (see  Table  3). 
Even worse, according to a Ministry of Personnel 
(MOP)’s  estimation,  about  580,000  Chinese 
students have  left  the country  to  study since  the 
late 1970s, with only about 160,000 returning (Li 
et  al.,  2004).  Of  the  nearly  300,000  Chinese 
students overseas at present, one-third are involved 
in the biotechnology field. This seriously limits the 
source of research personnel supply. On the other 
hand,  although  universities  and  public  research 
institutions are capable of conducting world-class 
research, their activities are not connected to the 
budding  industrial  sector.  Patent  statistics  reveal 
  Performance sectors   
Source of 
  funding 
Research  
institutes  Enterprises  Universities  Others  Total 
Government  344.3  62.6  108.8  7.8  523.6 
Enterprises  22.4  1189.3  74.5  5.1  1291.3 
Abroad  2.6  19.8  2.6  0.1  25.2 
Others  62.4  42.3  14.9  6.6  126.2 
Total  431.7  1314.0  200.9  19.7  1966.3 
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that public research institutes and universities own 
80% of all biotechnology patents, but only 6% of 
new  biotechnology  therapeutics  and  vaccines  in 
China  are  the  result  of  joint  developments  by 
universities and enterprises (Liu, 2006).   
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Figure 2. Expenditure for new products of pharmaceutical 
industry (100 million yuan) 
Source: National Bureau of Statistics et al, China Statistics 
Yearbook on High Technology Industry (2004). 
Table 3 Biotechnology industry by country 
Item  China  India  USA  Germany 
Bio-tech   
Company 
>500  240  1460  365 
Personnel  50,000  25,000  140,000  14,000 
Laboratory  400  —  500  — 
R&D 
  Personnel  20,000  —  —  — 
Bio-tech 
park 
20  — 
5 
bio-tech 
zone 
— 
Source: Bio-industry in China annual report 2005 
Along with the growing foreign-capital investment 
and  rapid  reforms  and  reorganization  among 
domestic enterprises, we argue, it is an advantage 
for domestic biotechnology enterprises to establish 
a  sound  competitive  cooperation.  Furthermore, 
several  large-scale  groups  should  be  established 
via  strategic  alliances  such  as  mergers  and 
acquisitions.  In  this  way,  market  expansion  and 
enhancement of strength can be achieved with an 
enlarging  enterprise  scale  and  trade  value.  To 
overcome the barrier of limited funding and low 
investment, the Chinese government needs to take 
measures  such  as  simplifying  foreign  investment 
procedures, protecting the natural environment and 
improving  infrastructure  so  as  to  make  the 
investment environment more attractive. It is even 
more  important to construct an industrial  culture 
within  the  networks  of  China’s  biotechnology 
industry.  Cultural  differences  between  foreign 
investors  and  Chinese  staff  can  delay  the 
enrollment  of  foreign  investment  to  the  actor 
networks  of  China,  and  cultural  differences 
between nations cannot be removed within a short 
time; the industrial culture thus becomes crucial.       
To  deal  with  the  insufficiency  of  research 
personnel and domestic collaboration, we argue, a 
national  system  of  innovation  should  be  set. 
Taking  its  advanced  capability  in  genomics/ 
genetics  research,  the  networks  of  China’s 
biotechnology industry can translate their interests 
into  that  of  the  innovation  system  which  is 
promising in creating the waves of returnees from 
overseas  (Wong,  2006),  also  in  the  networks  of 
larger scale effectiveness of the overall operation 
of highly talented and skilled scientists. 
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